Edwards Lifesciences Corporation (NYSE: EW) announced new 5-year hemodynamic data from the PARTNER Trial demonstrating excellent durability of the first-generation ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE